{
    "abstract": "The Jada System\nWe conducted a descriptive subgroup analysis of the real-world RUBY registry to assess the safety and effectiveness of Jada for postpartum hemorrhage management in preterm births less than 34\u2009weeks (less than 28 wGA and 28 to less than 34 wGA). Of the 50 individuals treated, 24 had vaginal births and 26 had cesarean births.\nTreatment success rates were 85.7% at less than 28 wGA (81.8% vaginal [9/11], 100% cesarean [3/3]) and 88.9% at 28 to less than 34 wGA (100% vaginal [13/13], 82.6% cesarean [19/23]). No maternal deaths, uterine perforations, device expulsions, or serious adverse device effects (ADEs) were reported in either subgroup. Two nonserious ADEs were reported in 1 individual (endometritis and bacterial vaginosis); 2 individuals required hysterectomy (1 vaginal, 1 cesarean).\nResults for the less than 28 wGA and 28 to less than 34 wGA subgroups were consistent with the overall less than 34 wGA subgroup, which was previously shown to be consistent with births \u226534 wGA; however, continued attention to uterine size is warranted before device placement in births less than 34 wGA.\nClinicalTrials.gov; NCT04995887.",
    "authors": [
        {
            "affiliation": "The Ohio State University Wexner Medical Center, Columbus, OH, USA.",
            "firstname": "Kara M",
            "initials": "KM",
            "lastname": "Rood"
        },
        {
            "affiliation": "Mount Sinai Medical Center, New York, NY, USA.",
            "firstname": "Angela",
            "initials": "A",
            "lastname": "Bianco"
        },
        {
            "affiliation": "Ochsner Clinic, New Orleans, LA, USA.",
            "firstname": "Joseph R",
            "initials": "JR",
            "lastname": "Biggio"
        },
        {
            "affiliation": "University of Utah Health, Salt Lake City, UT, USA.",
            "firstname": "Marcela C",
            "initials": "MC",
            "lastname": "Smid"
        },
        {
            "affiliation": "Magee-Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.",
            "firstname": "Hyagriv N",
            "initials": "HN",
            "lastname": "Simhan"
        },
        {
            "affiliation": "Organon & Co, Jersey City, NJ, USA.",
            "firstname": "James",
            "initials": "J",
            "lastname": "Li"
        },
        {
            "affiliation": "Organon & Co, Jersey City, NJ, USA.",
            "firstname": "Candice",
            "initials": "C",
            "lastname": "Yong"
        },
        {
            "affiliation": "Organon & Co, Jersey City, NJ, USA.",
            "firstname": "Patricia I",
            "initials": "PI",
            "lastname": "Carney"
        },
        {
            "affiliation": "Organon & Co, Jersey City, NJ, USA.",
            "firstname": "Damien J",
            "initials": "DJ",
            "lastname": "Croft"
        },
        {
            "affiliation": "NewYork-Presbyterian/Columbia University Irving Medical Center, New York, NY, USA.",
            "firstname": "Dena",
            "initials": "D",
            "lastname": "Goffman"
        }
    ],
    "conclusions": "Results for the less than 28 wGA and 28 to less than 34 wGA subgroups were consistent with the overall less than 34 wGA subgroup, which was previously shown to be consistent with births \u226534 wGA; however, continued attention to uterine size is warranted before device placement in births less than 34 wGA.",
    "copyrights": null,
    "doi": "10.1080/14767058.2025.2451658",
    "journal": "The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians",
    "keywords": [
        "Postpartum hemorrhage",
        "blood loss",
        "maternal hemorrhage",
        "pregnancy complication",
        "uterine atony",
        "vacuum-induced hemorrhage-control device"
    ],
    "methods": null,
    "publication_date": "2025-02-10",
    "pubmed_id": "39924257",
    "results": "Treatment success rates were 85.7% at less than 28 wGA (81.8% vaginal [9/11], 100% cesarean [3/3]) and 88.9% at 28 to less than 34 wGA (100% vaginal [13/13], 82.6% cesarean [19/23]). No maternal deaths, uterine perforations, device expulsions, or serious adverse device effects (ADEs) were reported in either subgroup. Two nonserious ADEs were reported in 1 individual (endometritis and bacterial vaginosis); 2 individuals required hysterectomy (1 vaginal, 1 cesarean).",
    "title": "Real-world use of a vacuum-induced hemorrhage-control device in births <34 weeks gestational age.",
    "xml": "<Element 'PubmedArticle' at 0x788504a0ca40>"
}